Table 4.
Retrospective studies in the literature using EBRT + IGBT.
| Author | Number of Patients | Stage | CTV | Median D90 GTV GTV (Gy) QD2(α/β=10) | Median D90 CTV CTV (Gy) EQD2(α/β=10) | Relapses | OS% (y) | CSS% (y) | DFS% (y) |
|---|---|---|---|---|---|---|---|---|---|
| Gill et al., 2014 [14] | 14 | I | Uterus + cervix + 1–2 cm vagina | 138.0 ± 64.6 (mean ± SD) | 72.4 ± 6.0 (mean ± SD) | 1 local relapse | 2 y: 94.4 | - | - |
| Archaya et al., 2016 [15] | 15 | I–III | uterus and cervix | - | EBRT: 48–50.4 | 2/15 pelvis 5/15 M1 |
2 y: 64 | - | - |
| BT: 37 (31–56) | |||||||||
| Jordan et al., 2017 [16] | 9 | I | GTV + 2 cm | 100.5 (70.5–177.1) | 60.9 (48.1–74) | 1 local relapse 93.4% 4 y | - | - | - |
| Gebhardt et al., 2019 [17] | 16 | I | Uterus + cervix + 1 cm vagina | 115 (101.2–131.0) | 95.1 (52.8–116.2) | 96.8% 2 y | 2 y: 96.8 | - | 90.1 2 y |
| Espenel et al., 2020 [18] | 27 | I–IV | Uterus + cervix + outer residual tumour | 73.6 (64.1–83.7) | 60.7 (56.4–64.2) | - | 5 y: 63 | - | 49.7 5 y |
| Gannavarapu et al., 2020 [4] | 25 | I–III | Uterus, cervix, + upper third of vagina | - | 70.2 (51–88.7) | - | 2 y: 75 | 2 y: 100 | |
| Carpenter et al., 2023 [20] | 32 | I–IV | HR-CTV | - | HR-CTV > 91.3 | Favourable 100%. | 2 y: 65 | - | 77 2 y |
| IR-CTV | (88.8–102) | Unfavourable 50% | |||||||
| IR-CTV > 73.4 (69.9–76) | |||||||||
| Huang et al., 2023 [21] | 50 | I–III | Uterus + cervix + 1 cm vagina | 166.2 (123–189.8) | 72.9 (74.9–80.3) | - | 2 y: 75 | 2 y: 83 | - |
| Present series | 103 | I–III | Most uterus + cervix | 23/103 | 53/103 | 5 y: 18 uterine | - | 5 y: | 5 y: |
| 85.4 (58.5–189.79) | 75 Gy (55–132.7) | 27 nodal | I–II: 82.2 | I–I:64.2 | |||||
| (α/β = 4.5) | (α/β = 4.5) | 24 distant | III 56.7 | III:46.1 |
CTV: Clinical target volume. GTV: Gross tumoural volume. Y: years; HR-CTV: endometrium + cavity + tumour mass. IR-CTV: HR-CTV + 5 mm excluding organs at risk.